William King

Oct 5, 2023 | valuebasedcancer.com | William King

Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer (NSCLC).

Sep 10, 2023 | theoncologypharmacist.com | Patricia Stewart |William King

"Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC" was originally published by CCA News. Surufatinib, a small-molecule inhibitor targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R, has exhibited satisfactory clinical effectiveness and favorable safety and tolerability profiles when utilized as monotherapy in the treatment of patients with biliary tract cancer (BTC) in the second-line setting.

Sep 6, 2023 | oncpracticemanagement.com | William King

Copyright © 2023 Association for Accessible Medicines. Reprinted with permission.

Jun 21, 2023 | oncpracticemanagement.com | William King |Patricia A. Stewart |Nadia Jaber

“Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive” was originally published by the National Cancer Institute. It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief. The most recent evidence comes from a new study that suggests that the Y chromosome may actually protect men from aggressive bladder cancer.